.jpg "George Demetri, MD photo")
Professor and Director, Sarcoma Center
Dana-Farber Cancer Institute and Harvard Medical School
Boston, Massachusetts, United States
Dr. Demetri received his A.B. in biochemical sciences from Harvard College and M.D. from Stanford University, then pursued internal medicine residency and Chief Residency at the University of Washington, Seattle and medical oncology fellowship at the Dana-Farber Cancer Institute and Harvard Medical School. He co-directs the Ludwig Center at Harvard (with cell biologist Joan Brugge, PhD) to bring together more than 30 investigative teams to focus on understanding, overcoming, and preventing resistance to anticancer therapies. His career as a physician-scientist has focused on developing therapies targeting specific oncogenic mechanisms to treat precisely-defined subsets of sarcomas and other cancers. He was instrumental in the development of imatinib as the first effective therapy for gastrointestinal stromal tumor (GIST) as a paradigm of a mutation-driven solid tumor. His research efforts have subsequently contributed to U.S. FDA approval of multiple other therapies to treat GIST, other sarcomas as well as other malignancies. On the basis of this body of work, Dr. Demetri was awarded the 2020 David A. Karnofsky Memorial Award from the American Society of Clinical Oncology (ASCO).
Dr. Demetri recently co-founded a clinical stage biotech company (IDRx) in addition to scientific advisory roles for several biotech and pharma companies worldwide. A former member of the Board of Directors of the American Association for Cancer Research (AACR), he is a member and immediate past Chair of the AACR Science Policy and Government Affairs Committee.
Friday, March 24, 2023
3:15 PM – 3:45 PM
Disclosure information not submitted.